卢国良,王建伟,槐 斐,刘荷臣

背景：我中心尚缺乏帕唑帕尼在晚期肾癌患者中的临床有效性和安全性数据，本研究目的旨在探讨帕唑帕尼治疗晚期肾癌的疗效和不良反应，分析影响患者预后的因素。方法：本研究回顾性分析2019年10月至2021年11月收治的22例晚期转移性肾癌患者的临床资料，分别使用RECIST1.1版及CTCAE5.0版进行治疗效果和不良反应评估。主要终点为疾病无进展生存率（PFS），次要终点为总生存率（OS），疾病控制率（DCR），客观缓解率（ORR）。使用K-M法计算PFS和OS。通过单因素和多因素Cox比例风险回归模型评估与PFS和OS相关的影响因素。结果：本研究共纳入22例患者，在随访结束时，其中有4例因不良反应而减量甚至停药，10例疾病进展，12例在随访结束时疾病仍未出现进展，4例死亡。最常见的药物不良事件为口腔炎、高血压、毛发变白及手足综合征。最常见的3-4级不良事件为高血压。PFS为9.83个月(95%CI 8.82-10.84)，OS为22.57个月(95%CI 6.70-38.44)。DCR为54.55％，ORR为9.1％。Cox比例风险模型分析显示影响OS的独立危险因素为年龄＞65岁结论：本研究的结果显示帕唑帕尼在治疗晚期转移性肾细胞癌患者方面疗效显著，患者对药物所致的不良反应耐受较好，3-4级不良反应较少发生。年龄＞65岁有可能是影响肾癌预后的危险因素。

肾细胞癌；Pazopanib；真实世界研究；回顾性分析

[1] Hsieh,J.J.,et al.,Renal cell carcinoma.Nature Reviews Disease Primers,2017.3(1). [2] Gharib,K.E.,Adjuvant therapy in renal cell carcinoma:is resection still solely enough?Future Oncology,2021.17(6):p.633-636. [3] Erman,M.,et al.,Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific,North Africa,and Middle East regions:PARACHUTE study.BMC Cancer,2021.21(1). [4] Miyamoto,S.,et al.,Drug review:Pazopanib.Japanese Journal of Clinical Oncology,2018.48(6):p.503-513. [5] Sternberg,C.N.,et al.,Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma:Results of a Randomized Phase III Trial.Journal of Clinical Oncology,2010.28(6):p.1061-1068. [6] Motzer,R.J.,et al.,Pazopanib versus sunitinib in metastatic renal-cell carcinoma.N Engl J Med,2013.369(8):p.722-31. [7] Schmidinger,M.,et al.,Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma(PRINCIPAL Study).Oncologist,2019.24(4):p.491-497. [8] Eisenhauer,E.A.,et al.,New response evaluation criteria in solid tumours:Revised RECIST guideline(version 1.1).European Journal of Cancer,2009.45(2):p.228-247. [9] Motzer,R.J.,et al.,Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma:Final Overall Survival Analysis of the Phase 3 PROTECT Trial.European Urology,2021.79(3):p.334-338. [10] Sternberg,C.N.,et al.,Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma:Results of a Randomized Phase III Trial.Journal of Clinical Oncology,2010.28(6):p.1061-1068. [11] Sheng,X.,et al.,Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma:pooled subgroup analysis from the randomized,COMPARZ studies.BMC Cancer,2020.20(1). [12] Ruiz-Morales,J.M.,et al.,First-line sunitinib versus pazopanib in metastatic renal cell carcinoma:Results from the International Metastatic Renal Cell Carcinoma Database Consortium.European Journal of Cancer,2016.65:p.102-108. [13] Pak,S.,et al.,Association between Postoperative Detection of Circulating Tumor Cells and Recurrence in Patients with Prostate Cancer.J Urol,2020.203(6):p.1128-1134. [14] Albiges,L.,et al.,TiNivo:safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma.Ann Oncol,2021.32(1):p.97-102. [15] Motzer,R.J.,et al.,Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.The New England journal of medicine,2019.380(12):p.1103-1115. [16] Escudier,B.,et al.,Renal cell carcinoma:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-updagger.Ann Oncol,2019.30(5):p.706-720. [17] Fizazi,K.,et al.,Nonmetastatic,Castration-Resistant Prostate Cancer and Survival with Darolutamide.The New England journal of medicine,2020.383(11):p.1040-1049.

点击下载PDF